The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
SparkCures Verified Accurate, up-to-date information. Learn more
A Phase 1b/2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedul...
RADIATION + TALQUETAMAB FOR EXTRAMEDULLARY DISEASEA Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multipl...
ELRANATAMAB AS CONSOLIDATIONA Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Tre...
TALQUETAMAB WITH IBERDOMIDEMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
MRD-GUIDED ELRANATAMAB MAINTENANCE THERAPYMMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
HORIZON ADAPTIVE PLATFORMPhase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multipl...
CEVOSTAMAB AFTER CAR-T CELL THERAPYPre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With...
PRE AND POST TRANSPLANT ELRANATAMABProvide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
LINVOSELTAMAB - COMPASSIONATE USEThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
SparkCures Verified Accurate, up-to-date information. Learn more
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
MRD-GUIDED ELRANATAMAB MAINTENANCE THERAPYPre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With...
PRE AND POST TRANSPLANT ELRANATAMABThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
A Phase 1b/2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedul...
RADIATION + TALQUETAMAB FOR EXTRAMEDULLARY DISEASEA Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Tre...
TALQUETAMAB WITH IBERDOMIDEThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
A Phase 1b/2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedul...
RADIATION + TALQUETAMAB FOR EXTRAMEDULLARY DISEASEA Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multipl...
ELRANATAMAB AS CONSOLIDATIONA Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Tre...
TALQUETAMAB WITH IBERDOMIDEPhase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multipl...
CEVOSTAMAB AFTER CAR-T CELL THERAPYThe following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).